The seven antigenically distinct serotypes of Clostridium botulinum neurotoxins cleave specific SNARE complex proteins and block the release of neurotransmitters causing flaccid paralysis and are considered potential bioweapons. Botulinum neurotoxin type A is the most potent among the clostridial neurotoxins and to date there is no post exposure therapeutic intervention available. In order to develop inhibitors leading to drug design, it is imperative that critical interactions between the enzyme and the substrate near the active site are known. While enzyme-substrate interactions at exosites away from the active site are mapped in detail for botulinum neurotoxin type A, information about the active site interactions is lacking. Here, we present the crystal structures of botulinum neurotoxin type A catalytic domain in complex with four inhibitory substrate analog tetrapeptides, viz. RRGC, RRGL, RRGI and RRGM at resolutions 1.6 to 1.8Å. These structures show for the first time the interactions between the substrate and enzyme at the active site and delineate residues important for substrate stabilization and catalytic activity. We show that OH of Tyr366 and NH2 of Arg363 are hydrogen bonded to carbonyl oxygens of P1 and P1' of the substrate analog and position it for catalytic activity. Most importantly, the nucleophilic water is replaced by the amino group of the N-terminal residue of the tetrapeptide. Further, S1' site is formed by Phe194, Thr215, Thr220, Asp370, and Arg363. K i of the best inhibitory tetrapeptide is 157 nM.
Botulinum (BoNT) and tetanus (TeNT) neurotoxins are causative agents of botulism and tetanus, serious neurological disorders. Their LD 50 's in humans are in the range of 0.1 -1 ng per kg (1, 2) , which make them the most poisonous substances known. They are listed as Category A bioterror agents by the Centers for Disease Control and Prevention (CDC). Of the seven serotypes (A to G) produced by Clostridium botulinum, BoNT/A, B, and E (and possibly C and F) have been implicated in cases of botulism in humans with BoNT/A being the most potent of them. Clostridium neurotoxins (CNT) are synthesized as single inactive polypeptide chains (150 kDa) and released as active dichains (heavy, 100 kDa, H and Light, 50kDa, L) held together by an interchain disulfide bond after cleavage by proteinases (3) (4) (5) (6) . BoNTs act via a four-step process involving (i) cell binding, (ii) internalization, (iii) translocation into the cytosol and (iv) enzymatic modification of a cytosolic target (7) (8) (9) (10) (11) . BoNTs block the release of acetylcholine at the neuromuscular junction causing flaccid paralysis while TeNT blocks the release of neurotransmitters like glycine and γ-aminobutyric acid in inhibitory interneurons of the spinal cord resulting in spastic paralysis. In spite of different clinical symptoms, these etiological agents intoxicate neuronal cells in the same way and have similar functional and structural organizations (12) (13) (14) (15) . Light chain is the catalytic domain and acts as a zinc endopeptidase on specific components of the neuroexocytosis apparatus in target cell's cytosol. BoNT A and E cleave SNAP-25 while BoNT B, D, F and G cleave VAMP at specific peptide bonds. BoNT/C is unique since it is the only CNT capable of cleaving two substrates, SNAP-25 and syntaxin (16).
Since they are Category A bioterror agents, it is imperative that counter measures are developed to block their toxicity by targeting any one of the four steps in their mechanism of action. Here, we present the design and structural basis of inhibitors to block the catalytic activity of BoNT/A serotype. Though it is desirable to have full-length BoNT/A-LC structure for inhibitor studies, we cloned BoNT/A-LC (1-424) (hereafter called Balc424) which is as active as wild type since full length light chain was not amenable to crystallization (17) .
Materials and Methods

Cloning
The DNA encoding LC 1-424 was PCR amplified using the forward primer 5'-ATGACCATGGGCATGCCATTTGTTAA TAAAC-3' which adds an NcoI restriction site to the 5' end and the reverse primer 5'-CCGCTCGAGTTCAAACAATCCAG-3' bearing a XhoI restriction site to the 3' end.
The PCR product was subcloned into pET28b(+) vector (Novagen) using the NcoI and XhoI restriction sites. The BoNT/A full length LC plasmid, a kind gift from Thomas Binz, was used as the template for PCR.
Expression and Purification
The plasmid encoding Balc424 was transformed into E. coli BL21(DE3)-RIL cells (Stratagene). Cells were inoculated into ZYP 5052 media containing antibiotics and grown at 37°C to an OD 600 of about 0.6. The cells were then allowed to auto-induce overnight at 18°C (18) . Cells were harvested and the C-terminal hexahistidine tagged protein was purified on Ni-NTA resin (Qiagen) by standard techniques. Fractions containing Balc424 protein were concentrated and loaded onto a size-exclusion (S-200) column previously equilibrated with 2 mM DTT, 200 mM NaCl, and 20 mM HEPES at pH 7.4 buffer. The purified protein was then stored at -80°C. Protein concentration was determined from ε 280 = 45.4 M -1 cm -1 .
Crystallization and Data collection
Balc424 crystals were grown using the sitting drop vapor diffusion method at room temperature. Equal volumes (2 µl) of protein (20 mg/ml) and reservoir solutions were mixed and equilibrated against 800 µl reservoir solution containing 15% (w/v) PEG 3350, 0.3 M ammonium sulfate and 100 mM Bis-Tris buffer at pH 6.8. Plate-like crystals obtained in a week were flash frozen in liquid nitrogen after transferring to the mother liquor containing 15% ethylene glycol as cryoprotectant. X-ray data were collected at beamline X29 of the NSLS using a wavelength of 0.979 Å. Balc424 crystals diffract to at least 1.7 Å resolution. Data were indexed, processed and scaled using HKL2000 (19) 
Structure determination and refinement
The crystal structure was determined by molecular replacement with MOLREP in the CCP4 program suite (20) . The catalytic domain (residues 10 to 420) of the full holotoxin type A (pdb id 3BTA) was used as a search model, after removing flexible loops. Rigid-body refinements of initial solution followed by simulated annealing with CNS gave an excellent electron density map (21) . Residues not included in the search model were built using 'O' and the model was further refined (22) . The final R and R free are 20.6% and 24.1%, respectively. The final model contains residues 1 to 423, two sulfate ions and 230 waters. In addition to these, the model contains an acetate ion that co-ordinates to zinc in a bidendate fashion. Residue424 and the Cterminal histag were not modeled because of weak or missing electron density.
Balc424:tetrapetide Complexes
Balc424 was co-crystallized individually with tetrapeptides (RRGC, RRGM, RRGL and RRGI amides) by the sitting drop vapor diffusion method at room temperature using conditions similar to native protein. Balc424 was mixed with greater than 10 fold molar excess of the tetrapeptide for co-crystallization trials. Balc424 gave better complex crystals with RRGC, RRGM, RRGL and RRGI at stoichiometric ratios of 1:30, 1:30, 1:40 and 1:40, respectively. Structures of the complexes were determined by rigid-body refinement of Balc424 model followed by stimulated annealing. Both the composite omit map and the difference Fourier map showed interpretable electron density for all the tetrapeptides. In RRGC, the residual density near the Sγ atom of P3' Cys was modeled as sodium ion. Initial attempts to model this residual density as water molecule or sulfenic acid of P3' Cys were unsuccessful. Residual densities elsewhere were modeled as sulfate ions in all four complexes. The respective models were refined using CNS.
The data and refinement statistics are given in Table 1 . To confirm the sulfur position in RRGC and RRGM complexes, redundant data were collected at wavelength 1.54 Å. The anomalous difference Fourier maps computed with the model phases (excluding the tetrapeptide) clearly showed the sulfur position of cysteine and methionine thus confirming the orientation of the peptide.
Results and Discussion
Structure of wild-type Balc424
The crystal structure of Balc424 was determined by the molecular replacement method using the light chain of holotoxin (pdb id: 3BTA) as a search model. The asymmetric unit contains one molecule of Balc424 with an acetate ion at the active site replacing the nucleophilic water ( Figure 1 ). The structure of Balc424 is essentially similar (root-mean square deviation [RMSD] of ~1.3 Å for Cα atoms) to reported structures of BoNT/A light chain except for the structural changes in 200 and 250 loops (12, 17, (23) (24) (25) (26) (27) . These loops pack against 370 loop and take a helical conformation ( Figure  1A ) unlike other light chain structures where they are disordered. The electron density for these loops is well defined showing ordered secondary structures, implying that this might be the most stable arrangement for this region. This may also be due to the allosteric effect of the acetate ion binding in the active site.
Active site of CNTs is characterized by a strictly conserved HEXXH + E motif and a catalytic zinc ion. A water molecule coordinated to zinc ion and hydrogen bonded to the conserved glutamate of the HEXXH motif acts as a nucleophile for the proteolytic reaction. In the current structure, zinc takes hexa coordination from nitrogen atoms (NE) of His223 and His227, carboxylate oxygens of Glu262 and acetate ion in a bidendate fashion ( Figure 1B ).
Oxygen atoms of carboxylate group of acetate ion are hydrogen bonded to Glu224 and the hydroxyl group of Tyr366 with one of them replacing the nucleophilic water. In BoNT/B structure, the nucleophilic water is replaced by a sulfate ion and such a replacement has been commonly observed in other enzymes (14, 24) . Mutating Glu224 to Gln or Ala abolishes the catalytic activity completely while mutating Tyr366 to Phe or Ala reduces the activity in BoNT/A and E (28) (29) (30) (31) . Accordingly, Glu224 is essential and acts as a general base for the activation while Tyr366 is required for stabilizing the transition state intermediate. Glu351 is hydrogen bonded to His223 and also forms a salt bridge with Arg363. These interactions are essential to keep the active site geometry intact and maintain the charge distribution that is essential for substrate binding and catalysis. They are also observed in other serotypes suggesting that all BoNTs follow similar catalytic mechanism. This is the first crystal structure of BoNT/A catalytic domain with one molecule per asymmetric unit and with the active site exposed to solvent region unobstructed by crystal packing making this crystal form ideal for inhibitor complex studies.
Substrate Binding and Catalysis
CNTs hydrolyze specific peptide bonds in the neuronal SNARE proteins (32) . For example, BoNT/A cleaves the peptide bond Gln197-Arg198 of SNAP-25. It is known that CNTs recognize the substrate at remote regions away from the active site called exosites to undergo efficient hydrolysis (33) (34) (35) (36) (37) . The crystal structure of the complex between the double mutant (Tyr366Phe/Glu224Gln) of Balc and SNAP-25 (146-204) peptide has provided information about exosites, substrate recognition and substrate binding mode (23). But the critical interactions between the enzyme and the substrate at the proteolytic site are missing probably due to the introduced mutation. In order to fill this information gap and understand the interactions between the substrate and BoNT/A at the active site, we determined the high-resolution crystal structures of Balc424 in complex with inhibitory tetrapeptides (partly mimicking the substrate), RRGX, where X = C, M, L or I. These peptides are designed to mimic the substrate scissile bond (P1 and P1') and for optimal binding (P2' and P3') as well as for inhibition.
Balc424 was co-crystallized with tetrapeptides RRGC, RRGM, RRGL and RRGI (all containing C-terminal amide group) and are hereafter referred to as such to represent the complexes ( Table 1 ). The native Balc424 structure was used as the starting model with data collected from crystals of complexes. Models of tetrapeptides were fitted unambiguously in the difference Fourier maps calculated after rigid-body refinement followed by simulated annealing refinement with CNS ( Figure 2 ). The orientation of the tetrapeptide was verified and confirmed by the anomalous signal from sulfur (Cys/Met).
Crystal structures of Balc424-tetrapeptide complex provide substantial information about the substrate binding mode and its essential and critical interactions for proteolysis at the active site. Overall, structure and active site of Balc424 in all four tetrapeptide complexes are similar to acetate ion bound native structure (RMSD of ~1.0Å for 400 common Cα atom pairs). Also, the overall binding mode, orientations and molecular interactions of all four tetrapeptides with the enzyme are similar except for the side chain conformation of the second arginine ( Figure  3A) . The tetrapeptides are tightly bound to the protein (average B-factor and buried surface area for the peptides, Table 1 ) and mostly interact with 200, 250 and 370 loops.
In all four structures, the nitrogen atom of the N terminal amino group of the tetrapeptide replaces the nucleophilic water and coordinates with zinc and forms hydrogen bonds with the general catalytic base Glu224 ( Figure  3B and 3C) . The guanidinium group of the first arginine in the tetrapeptide forms a salt bridge with Glu164 in the S1 subsite while the side chain of the second arginine of the peptide binds in the S1' pocket and makes a salt bridge with Asp370 ( Figures 3 and 4) . In addition to the salt bridge, the guanidinium group of second arginine stacks between the guanidinium group of Arg363 and Phe194. Mutation of Glu164 or Asp370 reduces the catalytic activity of BoNT/A indicating that these residues are important for substrate binding and positioning of the scissile bond for nucleophilic attack and proteolysis (25, 38) . Therefore, it is reasonable to say that the first two arginines of the tetrapeptide mimic P1 and P1' of the substrate and accordingly are called P1 and P1', hereafter. Significant reduction in enzymatic activity was observed when Tyr366 was mutated to Phe (30, 38) and here Tyr366 OH forms a strong hydrogen bond with P1 carbonyl oxygen confirming that Tyr366 stabilizes the tetrahedral intermediate of the carbonyl carbon of P1 (28, 39) . Moreover, this carbonyl oxygen forms coordination bond with zinc ion resulting in zinc having six coordinations with distorted octahedral geometry.
In Balc-SNAP-25 (146-204) structure, the crucial interactions between the scissile bond of P1 and P1' residues (Gln197-Arg198) of SNAP-25 and active site are missing, probably due to the double mutation. This is the first structural study showing critical interactions between the substrate and BoNT/A at the proteolytic site responsible for catalytic activity.
Arg363 and Glu351 are conserved across all serotypes and their role in catalytic activity has been established both by mutational and structural studies in BoNT/E and BoNT/A (28, 30, 40) . In addition to interactions similar to native structure, the side chain of Arg363 is hydrogen bonded to P1' carbonyl oxygen and helps in positioning the substrate for catalytic activity. In all four structures, the S1' site is formed by Phe194, Thr215, Thr220, Arg363 and Asp370. Also, the C-terminal amide oxygen of the tetrapeptide makes hydrogen bond with the backbone nitrogen of Asp370. These interactions are common in all four Balctetrapeptide complex structures (Figure 4 ). The C-terminal side chain of the tetrapeptide is packed against the hydrophobic pocket that is composed of Pro206, Leu207, Tyr250, Tyr251, Met253, Leu256, Phe369 and Phe423 ( Figure 5 ). Ten water molecules in the vicinity of active site and tetrapeptide are involved in stabilizing the complex.
Enzymatic mechanism
The present structures of enzyme:tetrapeptide complexes could represent the Michaelis complex formation though the P1 amino group replaces the nucleophilic water ( Figure 3C ). While P1 carbonyl oxygen forms coordination with zinc ion and also hydrogen bonds with OH of Tyr366, P1' carbonyl oxygen is hydrogen bonded to NH1 of Arg363. These two interactions position and stabilize the substrate for catalytic action. Based on our structural and available biochemical information, we are proposing the following catalytic mechanism. Glu224 acts as a general base by abstracting a proton from the nucleophilic water. The nucleophilic water attacks the carbonyl carbon of the scissile bond which forms the tetrahedral transition state ( Figure 6 ). The zinc ion and Tyr366 might stabilize this intermediate tetrahedral transition state. The shuttling of protons with the help of Glu224 assists subsequent formation of stable leaving amino group. This model is consistent with our model proposed for BoNT/B and BoNT/E and is similar to thermolysin (29, 39, 41) .
Substrate Based Inhibitor
Developing substrate-based peptide inhibitor is a common strategy for designing inhibitors for proteases. Recently, crystal structures of BoNT/A light chain in complex with inhibitors L-arginine hydroxamate, 4-chlorocinnamic hydroxamate and 2,4-dichlorocinnamic hydroxamate have been reported (17) . These inhibitors inhibit utmost at 300 nM levels. In this study we used substrate and structure based approaches to search for better inhibitors. The inhibitor was designed based on two main criteria: the charge distribution in the active site cavity and the substrate proteolytic site (42) . Figure 7 shows the electrostatic surface potential diagram for BoNT/A active site. It is evident that the zinc binding region is mostly negatively charged and the region where loops 200, 250 and 370 come together is hydrophobic. Accordingly, the inhibitor should have positively charged residues at one end and hydrophobic ones on the other to enhance the binding affinity. BoNT/A cleaves at the peptide bond between Gln197 (P1) and Arg198 (P1') of SNAP-25. P1' was maintained as Arg as in the substrate since it maintains the positive charge and also fits well at the S1' site.
Moreover, P1' is critical for the substrate binding (43) . P1 was changed to Arg from Gln to enhance positive charge. Based on this we designed four tetrapeptides, RRGC, RRGM, RRGL and RRGI, all of them having hydrophobic residues of varying size at the C terminus. The K i determined for the inhibitors with a 17-mer SNAP-25 substrate peptide using the full length Balc were 157 nM, 660 nM, 786 nM and 845 nM for RRGC, RRGL, RRGI and RRGM, respectively. When the assay was done in the presence of ZnCl 2 and DTT, IC 50 for RRGC significantly increased but those of the other three were unaffected (Ludivico, Swaminathan & Ahmed, 2008, unpublished) . The latter three or their derivatives potentially being free from intracellular redox environment should thus be suitable for further studies as drug candidates. This is the first report of a high affinity, small peptide inhibitor of BoNT/A protease activity in solution and the structural study in complex with the target.
Analysis of intermolecular forces between the enzyme and peptide molecule indicates that the N terminal arginines of the tetrapeptides play a vital role in the binding of inhibitor to the enzyme. As we expected the two N-terminal arginines of the peptide inhibitor fit in the acidic region and the C-terminal hydrophobic residue (P3') of all four (Cys, Met, Leu and Ile) pack against the hydrophobic region (Figs 3 and 5) . P2' Gly acts as a flexible linker between the two. The salt bridges formed by the N-terminal P1 Arg with Glu164 and P1' Arg with Asp370 anchor the inhibitor for binding. The nucleophilic water has been displaced by the amino group of P1 and is not available for catalytic activity. The optimum length for a peptide inhibitor has been suggested to be a heptapeptide (14, 24) . However, we find that the tetrapeptide in our case has lower K i than the heptapeptide. However, it is worth exploring effects of adding residues to the C terminus. The structural work presented here will form the basis for design of more potent inhibitors for this neurotoxin. For refinement all observed reflections were included. 
